Login / Signup

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.

Giandomenico RovielloElisabetta GambaleRoberta GiorgioneDaniele SantiniMarco StellatoGiuseppe FornariniSara Elena RebuzziUmberto BassoDavide BimbattiLaura DoniGabriella NesiMelissa BersanelliSebastiano ButiUgo De GiorgiLuca GalliAndrea SbranaRaffaele ConcaClaudia CarellaEmanuele NaglieriSandro PignataGiuseppe ProcopioLorenzo Antonuzzo
Published in: Cancer medicine (2022)
After treatment with both nivolumab and cabozantinib, the choice of a safe active systemic therapy offered better outcomes than BSC.
Keyphrases
  • metastatic renal cell carcinoma
  • healthcare
  • palliative care
  • quality improvement
  • type diabetes
  • adipose tissue
  • bone marrow
  • cell therapy
  • weight loss